Bair, Daniel
(2014)
The Incidence of Bisphosphonate Related Osteonecrosis of the Jaw Following a Single Dose of 5mg Zoledronic Acid for the Treatment of Osteoporosis in Frail, Elderly Institutionalized Women.
Master's Thesis, University of Pittsburgh.
(Unpublished)
This is the latest version of this item.
Abstract
Osteoporosis is a bone disease characterized by a decrease in bone mass and increased risk of bone fracture. Osteoporosis disproportionally affects older members of society and if untreated, is associated with high rates of morbidity, can significantly affect the quality of life and dramatically increases the risk of secondary life-threatening complications. In 2007, the FDA approved the utilization of yearly intravenous infusions of the bisphosphonate zoledronic acid as a treatment for advanced cases of osteoporosis. Unfortunately, zoledronic acid has been associated with the development of an oral condition known as bisphosphonate related osteonecrosis of the jaws (BRONJ). The purpose of this clinical trial was to evaluate the incidence of bisphosphonate related osteonecrosis of the jaws following a single dose of zoledronic acid for the treatment of osteoporosis in frail, elderly, institutionalized females. Utilizing a longitudinal prospective study design, data was collected from one hundred eighty subjects who were randomly assigned to receive a single intravenous infusion of either zoledronic acid (5mg) or placebo. Dental evaluations were completed at baseline (Day 0) and at months 12 and 24. All patients received daily supplemental calcium and vitamin D throughout the course of the trial. Patients completed a questionnaire to provide information regarding their oral hygiene practices to ascertain information that may be helpful in detecting risk factors for development of BRONJ. Zero cases of osteonecrosis were detected at any time point in the 180 subjects who completed the 24-month follow up period. Subjects' race, age, smoking status, oral hygiene practices, frequency of dental visits and use of a removable dental prosthesis did not contribute to the development of BRONJ. The results of this study suggest that the administration of a single dose of 5mg of zoledronic acid for the treatment of osteoporosis in frail, elderly, institutionalized women does not cause bisphosphonate related osteonecrosis of the jaw.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
University of Pittsburgh ETD
|
| Status: |
Unpublished |
| Creators/Authors: |
|
| ETD Committee: |
|
| Date: |
20 June 2014 |
| Date Type: |
Publication |
| Defense Date: |
28 March 2014 |
| Approval Date: |
20 June 2014 |
| Submission Date: |
10 June 2014 |
| Access Restriction: |
5 year -- Restrict access to University of Pittsburgh for a period of 5 years. |
| Number of Pages: |
30 |
| Institution: |
University of Pittsburgh |
| Schools and Programs: |
School of Dental Medicine > Dental Science |
| Degree: |
MDS - Master of Dental Science |
| Thesis Type: |
Master's Thesis |
| Refereed: |
Yes |
| Uncontrolled Keywords: |
Osteoporosis, Bishphosphonate, Zoledronic Acid, BRONJ, Osteonecrosis |
| Date Deposited: |
20 Jun 2014 14:19 |
| Last Modified: |
20 Jun 2019 05:15 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/21926 |
Available Versions of this Item
Metrics
Monthly Views for the past 3 years
Plum Analytics
Actions (login required)
 |
View Item |
![[feed]](/images/feed-icon-32x32.png){kind=icon}